Maxim Maintains Buy On IsoRay Following Fiscal 1Q:15 Results
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on IsoRay Inc (NYSE:ISR) with a $5 price target, following the company’s fiscal first-quarter results of 2015, posting revenues of just $1M with a net loss of $0.8 million, or $(0.01) per share.
Kolbert noted, “Sales of Proxcelan (Cs-131) in prostate cancer increased, but sales for other cancers were variable. We believe peer-reviewed publications in applications outside of prostate cancer will help drive market share penetration and increase usage.”
The analyst explained his price target stating, “We use FCFF, discounted EPS, and sum-of-the-parts models with a 10% discount rate to derive a $5.00 price target. Our metrics are driven by our assumptions for the market share penetration of Proxcelan (Cs-131 seeds), Cesitrex (Liquid Cs-131), and GliaSite (Catheter System) in prostate cancer, other cancers,and gliomas.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 5.6% and a 38.9% success rate. Kolbert has a -10.0% average return when recommending ISR, and is ranked #665 out of 3376 analysts.